Vargason AM, Anselmo AC, Mitragotri S
Safety Considerations and Contraindications Who Should Avoid CJC-1295 Ipamorelin Contraindications : Active cancer diagnosis (growth hormone can stimulate existing tumors) Pregnancy or breastfeeding Severe cardiovascular disease Uncontrolled diabetes Children and adolescents under 18 Potential Drug Interactions CJC-1295 Ipamorelin may interact with: Insulin and diabetes medications (can affect blood sugar) Corticosteroids (may blunt GH response) Thyroid medications (may require dose adjustments) Other hormone therapies Medical Supervision Requirements Consult healthcare providers before starting if you have: Diabetes or blood sugar issues Cardiovascular conditions History of cancer Current prescription medications Sleep disorders Our Clinics Experience with CJC-1295 Ipamorelin Dosing Through extensive clinical experience with CJC-1295 Ipamorelin protocols, weve observed optimal results with 200 mcg of each peptide administered before bed, 5 days per week
Moyer, V
Timing Optional Monitoring guidance is pathway-based because DSIP does not have established clinical lab-monitoring standards
At standard therapeutic doses (200 to 600 mcg daily), the amount of copper delivered is extremely small compared to dietary copper intake (the recommended daily intake of copper is 900 mcg from food)
However, brain and cervical spine MRIs were unremarkable, showing only a few stable unidentified bright objects (UBOs) in the subcortical white matter, without evidence of active demyelination
